Natural peptide · 24 amino acids · 2,687.2 Da

Humanin studies and research data

PepBank has 375 humanin studies with results. 201 of them gave humanin, with 1,067 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 1,067 results and 532 papers. Newer studies from Europe PMC

Results in people

0% of 1,067 results

Results in animals

527

49% of 1,067 results

Results in lab cells

536

50% of 1,067 results

From computer models

under 1% of 1,067 results

The molecule

Humanin identity

Identifiers, parent molecule, targets and development stage, from curated data.

Humanin (HN) was found in 2001 by a functional screen of a cDNA library from an Alzheimer disease brain. The cDNA encoded a 24-residue peptide that blocked neuronal death caused by familial Alzheimer disease genes and by amyloid-beta, but not death caused by polyglutamine (Q79) or mutant superoxide dismutase 1 (PMID 11371646, PMID 11717357). The sequence is MAPRGFSCLLLLTSEIDLPVKRRA (UniProt Q8IVG9). It matches an open reading frame inside the mitochondrial 16S rRNA gene MT-RNR2. UniProt adds a caution: if the sequence were translated inside mitochondria with the mitochondrial genetic code, the product would lack the last three residues, and the active peptide could instead come from one of about 13 related nuclear loci (MTRNR2L1 to MTRNR2L13; PMID 19477263). A 2002 study detected HN-immunoreactive protein of about 3 kDa in mouse testis and colon and in an Alzheimer brain, which supports in vivo production (PMID 12009529). Reported molecular actions, from cell and animal work: HN binds BAX and stops its move from cytosol to mitochondria (PMID 12732850); HN also binds BID and BimEL (UniProt Q8IVG9); HN binds IGFBP-3 at its 18-residue heparin-binding domain (PMID 14561895); HN is a ligand for the G protein-coupled receptors FPRL1 (FPR2) and FPRL2 (FPR3), and the N-formylated form is far more potent at FPRL1 (EC50 0.012 nM against 3.5 nM; PMID 15465011); and HN binds a receptor complex made of CNTFR, WSX-1 (IL27RA) and gp130 (IL6ST), which UniProt links to STAT3 signalling (PMID 19386761). HN also improved insulin action in rodents when given into the brain or as an analog by vein (PMID 19623253), and extended life span in C. elegans when overexpressed (PMID 32575074). The S14G analog (HNG, serine 14 replaced by glycine) is about 1000-fold more potent than HN in neuroprotection assays (PMID 16945331). Most animal intervention studies use HNG, not native HN. HNG is listed here as an alias because the same literature covers both. Colivelin is a different molecule: HNG17 with a C8R change, joined to the activity-dependent neurotrophic factor peptide ADNF (PMID 16267233); it is not covered by this record. Natural level studies are a large part of the literature. Circulating HN fell with age in humans and mice in one report (PMID 19623253). Plasma HN rose in old age and was highest in centenarians in a cohort of 693 people aged 21 to 113 (PMID 29955888). Circulating HN was higher in children of centenarians than in matched controls, and lower in Alzheimer disease and MELAS, in another report (PMID 32575074). These findings conflict on the age trend. No human trial that gives HN or HNG to a person was found. ClinicalTrials.gov lists 7 studies that mention humanin as of 2026-10-13. All of them measure HN levels or use HN as an outcome, and none tests it as a treatment. HN is not in the FDA 503A or 503B compounding lists or the FDA category 2 page, has no Drugs@FDA record, and has no entry in the EMA medicines or orphan designation data files. WADA does not name it in the 2026 or the 2027 List. The S0 class covers any pharmacological substance that no other section addresses and that has no current approval by a governmental regulatory health authority for human therapeutic use, so S0 applies by its wording (this is my reading of the List text, not a WADA statement).

Kind: Natural peptide · 24 residues
Identifiers: UniProtQ8IVG9 (opens in a new tab)ChEMBLCHEMBL4447799 (opens in a new tab)PubChem CID16131438 (opens in a new tab)UNIIH975EUX36G (opens in a new tab)CAS330936-69-1PDB1Y32 (opens in a new tab)KEGGC16068 (opens in a new tab)IUPHAR1047 (opens in a new tab)
Development: PreclinicalNo company holds an approval or a registered treatment programme for humanin. The peptide was first described by Hashimoto Y, Nishimoto I and colleagues (PNAS 2001, PMID 11371646).All intervention work is in cells and animals, mostly with the S14G analog HNG. ClinicalTrials.gov API v2 (query.term=humanin, 2026-10-13) returned 7 studies. Five are observational and plan to measure humanin in blood, muscle or tissue (NCT05506228 cerebral palsy muscle biopsies, NCT04104958 IVF in PCOS, NCT06125249 and NCT06105229 acute kidney injury, NCT03431844 cardiac surgery). Two are interventional studies that test other things (anaesthesia type, exercise) and list humanin as an outcome measure (NCT07678073 anaesthesia type in renal transplant, NCT07438002 exercise in dialysis). None gives humanin to participants. The terms colivelin and S14G returned 0 studies. Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
Target	Action	Evidence
N-formyl peptide receptor 2 (FPRL1)FPR2P25090 (opens in a new tab)	Agonist	primary literatureSource (opens in a new tab)
N-formyl peptide receptor 3 (FPRL2)FPR3P25089 (opens in a new tab)	Agonist	primary literatureSource (opens in a new tab)
Ciliary neurotrophic factor receptor subunit alpha (part of the trimeric humanin receptor)CNTFRP26992 (opens in a new tab)	Ligand that brings receptor subunits together	primary literatureSource (opens in a new tab)
Interleukin-27 receptor subunit alpha, WSX-1 (part of the trimeric humanin receptor)IL27RAQ6UWB1 (opens in a new tab)	Ligand that brings receptor subunits together	primary literatureSource (opens in a new tab)
Interleukin-6 receptor subunit beta, gp130 (part of the trimeric humanin receptor)IL6STP40189 (opens in a new tab)	Ligand that brings receptor subunits together	primary literatureSource (opens in a new tab)
Apoptosis regulator BAXBAXQ07812 (opens in a new tab)	Binds and blocks activation	primary literatureSource (opens in a new tab)
BH3-interacting domain death agonist (BID)BIDP55957 (opens in a new tab)	Binds and blocks activation	primary literatureSource (opens in a new tab)
Bcl-2-like protein 11 (BimEL isoform)BCL2L11O43521 (opens in a new tab)	Binds and blocks activity	primary literatureSource (opens in a new tab)
Insulin-like growth factor-binding protein 3IGFBP3P17936 (opens in a new tab)	Binding partner	primary literatureSource (opens in a new tab)

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

24 amino acids

H-

MAPRGFSCLL

LLTSEIDLPV

KRRA

-OH

Properties

From identity sources

Formula: C₁₁₉H₂₀₄N₃₄O₃₂S₂
Molecular weight: 2,687.2 g/mol
Monoisotopic mass: 2,685.4822 Da

UniProt Q8IVG9(opens in a new tab)retrieved 2026-10-13
PubChem CID 16131438(opens in a new tab)retrieved 2026-10-13
GSRS UNII H975EUX36G(opens in a new tab)retrieved 2026-10-13
ChEMBL CHEMBL4447799(opens in a new tab)retrieved 2026-10-13
ChEMBL CHEMBL4470851 (S14G analog HNG)(opens in a new tab)retrieved 2026-10-13
Curated KEGG C16068(opens in a new tab)retrieved 2026-10-13

Calculated from the sequence

pKa set

Average mass: 2,687.26 Da; Sum of ExPASy residue masses + water · ExPASy Compute pI/Mw; FindMod
Monoisotopic mass: 2,685.4822 Da; Sum of ExPASy residue masses + water · ExPASy FindMod
Isoelectric point (pI): 9.82; pH of zero net charge, EMBOSS pKa set · EMBOSS iep, Epk.dat
Net charge at pH 7.4: 1.87; Henderson-Hasselbalch, EMBOSS pKa set · EMBOSS iep, Epk.dat
GRAVY (hydropathy): 0.342; Mean Kyte-Doolittle hydropathy · Kyte and Doolittle 1982; Positive: hydrophobic on average.
Extinction coefficient, 280 nm (Cys reduced): 0 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam); No Trp or Tyr: absorbance at 280 nm cannot measure this peptide.
Instability index: 106.03; Dipeptide instability weights (DIWV) · Guruprasad et al. 1990; Above 40: classed as possibly unstable (ExPASy).
Aliphatic index: 117.9; Mole % A + 2.9 V + 3.9 (I + L) · Ikai 1980
Boman index: 1.27 kcal/mol; Mean solubility value (negated) · Boman 2003; 2.48 or below: lower protein-binding potential (Boman).
Hydrophobic moment (μH): 0.450; Eisenberg scale, 100° per residue, best 11-residue window · Eisenberg et al. 1982, 1984
pI with each pKa set: EMBOSS 9.82Bjellqvist (ExPASy) 9.49IPC peptide 10.05IPC protein 9.09

Defined and validated for proteins; use with care for short peptides.
Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

pI 9.82 · Net charge at pH 7.4: 1.87

Point or use arrow keys

Henderson-Hasselbalch, EMBOSS pKa set. Calculated, not measured.

Show as table

pH	Net charge
0	5.00
1	5.00
2	4.96
3	4.61
4	3.28
5	2.22
6	2.02
7	1.95
8	1.56
9	0.51
10	−0.08
11	−0.70
12	−1.66
13	−3.27
14	−3.91

Composition

Hydrophobic42% (10)A I L M V
Aromatic4% (1)F
Positive17% (4)K R
Negative8% (2)D E
Polar13% (3)S T
Special17% (4)C G P

24 residues. Each residue counts in one class; F and W count as aromatic.

A Ala2 · 8%

I Ile1 · 4%

L Leu5 · 21%

M Met1 · 4%

V Val1 · 4%

F Phe1 · 4%

W Trp0 · 0%

Y Tyr0 · 0%

H His0 · 0%

K Lys1 · 4%

R Arg3 · 13%

D Asp1 · 4%

E Glu1 · 4%

N Asn0 · 0%

Q Gln0 · 0%

S Ser2 · 8%

T Thr1 · 4%

C Cys1 · 4%

G Gly1 · 4%

P Pro2 · 8%

3D structure

ExperimentalPDB 1Y32

Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from RCSB PDB.

2D structure

Humanin has 24 residues. A full-atom drawing is hard to read at this size; the sequence view is the reference.

SMILES fromPubChem CID 16131438(opens in a new tab)

CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](C)NC(=O)[C@H](CCSC)N

Helical wheel

An ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.

μH, residues shown: 0.312
μH, best 11-residue window: 0.450
Arrow direction: 106°
Residues: 24 · 2 rings of 18

HydrophilicHydrophobic

Eisenberg consensus (normalized) scale · + K, R · − D, E

Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.

Show as table

Position	Residue	Angle	Eisenberg consensus (normalized)
1	M	0°	0.64
2	A	100°	0.62
3	P	200°	0.12
4	R	300°	-2.53
5	G	40°	0.48
6	F	140°	1.19
7	S	240°	-0.18
8	C	340°	0.29
9	L	80°	1.06
10	L	180°	1.06
11	L	280°	1.06
12	L	20°	1.06
13	T	120°	-0.05
14	S	220°	-0.18
15	E	320°	-0.74
16	I	60°	1.38
17	D	160°	-0.90
18	L	260°	1.06
19	P	0°	0.12
20	V	100°	1.08
21	K	200°	-1.50
22	R	300°	-2.53
23	R	40°	-2.53
24	A	140°	0.62

Results by area

Humanin results by year and outcome

Counts are exact and come from studies that gave the peptide.

Studies by year

375 of 532 studies have results (70%), published 2001 to 2026. Top row: every study. Bottom row: studies with results about Humanin, by class. The rows use different scales.

Studies
Human
Animal
Lab
Computer model
Natural levels, tool or combination only

Studies532 in all, 2001 to 2026

Studies with results375 in all, 2001 to 2026

Retracted studies are left out. A study with results in two classes counts in both.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

Humanin studies on brain and nerves

208 results · people 0 · animals 93 · lab 115

Top 5 of 208 results

In mice with induced stroke, HNG given before the stroke reduced the size of the brain damage.Stroke, 2006
In an animal model of retinal injury, humanin kept retinal function from declining.Aging cell, 2026
In cells, a humanin analogue protected several cell types from stress-induced death.The Journal of cell biology, 2018
In cells, humanin reduced IGFBP-3-induced cell death in a human glioblastoma cell line, but a mutant humanin did not.Proceedings of the National Academy of Sciences of the United States of America, 2003
In mice with a blocked brain artery, the humanin analog HNG reduced the size of brain damage.Brain research, 2010

Humanin studies on immune system and inflammation

136 results · people 0 · animals 83 · lab 53

Top 5 of 136 results

In mice on a high-cholesterol diet, humanin lowered a kidney inflammation marker.Life sciences, 2012
In mice with asthma, a humanin analog reduced lung weight increase compared with untreated asthmatic mice.Aging, 2023
In mice with induced stroke, a humanin analogue lowered TNF-alpha.IUBMB life, 2018
In mice prone to type 1 diabetes, humanin treatment led to fewer immune cells in the pancreas and milder damage.Metabolism: clinical and experimental, 2010
In mice, peptide treatment was linked to lower inflammatory cytokines in heart atria.Biomedicines, 2026

Humanin studies on cells, genes and aging

182 results · people 0 · animals 65 · lab 117

Top 5 of 182 results

In diabetic mice, humanin raised antioxidant levels in seminal fluid compared with untreated diabetic mice.Experimental physiology, 2026
In mice with induced ovarian insufficiency, a humanin derivative reduced cell death in ovarian support cells.Reproductive biomedicine online, 2024
In mice, peptide treatment was linked to better-looking mitochondria in heart atria.Biomedicines, 2026
In mice with low sperm counts, [Gly14]-humanin lowered reactive oxygen species in testis tissue.Andrology, 2025
In rats with induced heart injury, a humanin analogue did not change brain mitochondrial dynamics.Journal of Alzheimer's disease, 2018

Humanin studies on receptors and cell signals

193 results · people 0 · animals 50 · lab 139 · computer models 4

Top 5 of 193 results

In rats with PCOS, the benefit of added humanin involved a cell signalling path called Keap1/Nrf2.Molecular human reproduction, 2021
In mice on a high-cholesterol diet, humanin raised kidney levels of a protein that limits new blood-vessel growth.Life sciences, 2012
In male rats given paroxetine, humanin counteracted the drop in dopamine activity in two brain regions.Reproductive biology, 2026
In aged mice, a humanin analogue switched on the Akt/GSK-3beta pathway in the heart.American journal of physiology. Heart and circulatory physiology, 2018
In infected mice, humanin given beforehand dampened inflammation pathways in the liver, including NF-κB signaling.Pathogens, 2026

Humanin studies on sex hormones and fertility

81 results · people 0 · animals 50 · lab 31

Top 5 of 81 results

In diabetic mice, humanin reduced testicular tissue damage such as tubule degeneration and germ cell loss.Experimental physiology, 2026
In diabetic mice, S14G-humanin raised the share of live fetuses.Gynecological endocrinology, 2022
In male rats given paroxetine, humanin restored the balance of reproductive hormones.Reproductive biology, 2026
In male rats given paroxetine, humanin restored sperm quality measures.Reproductive biology, 2026
In diabetic mice, S14G-humanin increased fetal length.Gynecological endocrinology, 2022

Humanin studies on heart and blood vessels

68 results · people 0 · animals 49 · lab 19

Top 5 of 68 results

In mice, a humanin analogue made atrial fibrillation less easy to trigger.Biomedicines, 2026
In mice, HNG reduced blood clot formation in an injured artery compared with saline.Journal of cellular and molecular medicine, 2020
In mice with hemorrhagic shock, humanin-G improved blood pressure compared with vehicle.Shock, 2023
In mice prone to artery disease, a humanin analogue given for 16 weeks shrank fatty plaques in the main artery.Atherosclerosis, 2011
In mice, the humanin analog HNG shrank heart damage after blocked blood flow, most at 2 mg/kg.Arteriosclerosis, thrombosis, and vascular biology, 2010

Humanin studies on memory and thinking

26 results · people 0 · animals 24 · lab 2

Top 3 of 26 results

In mice, a more potent humanin form reversed the short-term memory impairment caused by scopolamine.British journal of pharmacology, 2001
In mice with induced memory loss, S14G-HN prevented a drop in short-term memory in a maze test.Journal of neuroscience research, 2005
In aged mice, humanin improved cognition.Scientific reports, 2018

Humanin studies on kidneys and bladder

16 results · people 0 · animals 15 · lab 1

Top 3 of 16 results

In mice on a high-cholesterol diet, humanin brought kidney small-vessel density back toward normal.Life sciences, 2012
In diabetic rats, a humanin analog lowered raised creatinine compared with untreated diabetic rats.Peptides, 2023
In mice with septic kidney injury, S14G-humanin treatment improved kidney function.Biochemical and biophysical research communications, 2024

Humanin studies on bones and joints

36 results · people 0 · animals 13 · lab 23

Top 3 of 36 results

In mice, adding HNG to bortezomib largely prevented the bone growth slowdown that bortezomib caused alone.Journal of the National Cancer Institute, 2014
In mice, HN treatment prevented the bone growth impairment that glucocorticoids caused.FASEB journal, 2019
In mice with arthritis, adding HNG to dexamethasone protected joint cartilage cells from cell death.Clinical and experimental rheumatology, 2020

Humanin studies on blood sugar

11 results · people 0 · animals 10 · lab 1

Top 5 of 11 results

In animals, humanin infused into the brain improved how well the body responds to insulin.PloS one, 2009
In mice prone to type 1 diabetes, 6 weeks of humanin brought blood sugar handling back to normal.Metabolism: clinical and experimental, 2010
In liver cells, humanin eased the harm that palmitate did to insulin signalling.Biochemical and biophysical research communications, 2020
In diabetic mice, humanin treatment changed blood sugar compared with untreated diabetic mice.Behavioural brain research, 2023
In mice prone to type 1 diabetes, 20 weeks of humanin delayed or prevented the start of diabetes.Metabolism: clinical and experimental, 2010

Humanin studies on cancer

14 results · people 0 · animals 9 · lab 5

Top 3 of 14 results

In mice with human tumors, HNG did not reduce the tumor-slowing effect of bortezomib.Journal of the National Cancer Institute, 2014
In mice with breast cancer, humanin lowered the rate of cell death in tumors.Scientific reports, 2020
In mice with human tumor grafts, HNG did not reduce the tumor-fighting effect of TMZ.Experimental and molecular pathology, 2019

Humanin studies on blood levels and clearance

8 results · people 0 · animals 8 · lab 0

Top 5 of 8 results

In mice, the humanin analogue HNGF6A stayed in the blood longer than the analogue HNG.Endocrinology, 2013
In rats with heart injury, HNG given during ischemia raised humanin levels in the damaged heart muscle.Cardiovascular therapeutics, 2017
In mice with a brain bleed, humanin given into a vein reached brain tissue around the bleed.The Journal of neuroscience, 2020
In mice, humanin given through the nose reached the brain, mainly along the trigeminal nerve routes.Theranostics, 2023
In mice lacking IGFBP-3, the humanin analogue HNG stayed in the blood longer than in normal mice.Endocrinology, 2013

Humanin studies on pain

7 results · people 0 · animals 7 · lab 0

Top 3 of 7 results

In diabetic mice, humanin lowered a pain-related protein that diabetes had raised.Archives of physiology and biochemistry, 2024
In mice with diabetes-type nerve pain, humanin raised the pain threshold compared with control mice.Neuropharmacology, 2025
In diabetic mice, humanin lowered a pain-related inflammatory protein that diabetes had raised.Archives of physiology and biochemistry, 2024

Humanin studies on stomach and gut

7 results · people 0 · animals 7 · lab 0

Top 3 of 7 results

In rats with intestinal injury, humanin improved the look of intestinal tissue compared with untreated rats.Pflugers Archiv, 2023
In rats with induced colitis, HNG treatment reduced weight loss.Saudi journal of gastroenterology, 2017
In rats with intestinal injury, humanin lowered a cell death marker compared with untreated rats.Pflugers Archiv, 2023

Humanin studies on skin, hair and wounds

11 results · people 0 · animals 5 · lab 6

Top 3 of 11 results

In mice, HNG lengthened the growth phase of the hair cycle.International journal of molecular sciences, 2020
In mice with a psoriasis-like skin condition, S14-G HNG injections improved skin histology.International immunopharmacology, 2022
In mice, HNG reduced cell death in hair follicles.International journal of molecular sciences, 2020

Humanin studies on survival and serious illness

10 results · people 0 · animals 5 · lab 5

Top 5 of 10 results

In mice with chemotherapy-induced ovarian damage, a Humanin analogue (HNG) reduced oxidative stress in the ovary.Molecular human reproduction, 2025
In an animal glioblastoma model, humanin treatment was linked to poorer survival than control.Cell death & disease, 2024
In mice with a serious Klebsiella infection, humanin at 5 mg/kg helped them live longer.Pathogens, 2026
In mice with hemorrhagic shock, humanin-G improved survival compared with vehicle.Shock, 2023
In cells, pretreatment with a Humanin analogue (HNGF6A) reduced cell death caused by oxidative stress.Bone & joint research, 2025

Humanin studies on cholesterol and blood fats

12 results · people 0 · animals 4 · lab 8

Top 5 of 12 results

In diabetic mice, S14G-humanin lowered LDL cholesterol.Gynecological endocrinology, 2022
In mice prone to artery disease, a humanin analogue did not lower cholesterol.Atherosclerosis, 2011
In diabetic mice, S14G-humanin lowered total cholesterol.Gynecological endocrinology, 2022
In lab-grown macrophages, HNG reduced the build-up of oxidized LDL cholesterol.Biochemical and biophysical research communications, 2017
In diabetic mice, S14G-humanin lowered HDL cholesterol.Gynecological endocrinology, 2022

Humanin studies on lungs and breathing

5 results · people 0 · animals 4 · lab 1

Top 4 of 5 results

In mice prone to artery disease, a humanin analogue given daily for 16 weeks prevented damage to the blood vessel lining.Atherosclerosis, 2011
In mice with hemorrhagic shock, humanin-G improved lung injury compared with vehicle.Shock, 2023
In mice prone to artery disease, a humanin analogue did not directly widen or narrow blood vessels.Atherosclerosis, 2011
In mice prone to artery disease, a humanin analogue kept up levels of an enzyme that helps blood vessels relax.Atherosclerosis, 2011

Humanin studies on hormones

4 results · people 0 · animals 4 · lab 0

Top 3 of 4 results

In diabetic mice, repeated humanin treatment restored leptin levels compared with untreated diabetic mice.Metabolites, 2026
In diabetic mice, repeated humanin treatment lowered asprosin levels compared with untreated diabetic mice.Metabolites, 2026
In diabetic mice, irisin levels rose somewhat with repeated humanin treatment compared with untreated diabetic mice.Metabolites, 2026

Humanin studies on liver

11 results · people 0 · animals 3 · lab 8

Top 3 of 11 results

In mice with a serious Klebsiella infection, humanin given beforehand was linked to less liver tissue damage.Pathogens, 2026
In mice with a serious Klebsiella infection, humanin given beforehand was linked to a lower liver enzyme, ALT, in blood.Pathogens, 2026
In mice with a serious Klebsiella infection, humanin given beforehand was linked to a lower liver enzyme, AST, in blood.Pathogens, 2026

Humanin studies on metabolism and nutrition

3 results · people 0 · animals 3 · lab 0

3 results

In obese mice, HNG changed the levels of amino acid metabolites in blood compared with vehicle.Metabolomics, 2019
In obese mice, HNG changed the levels of lipid metabolites in blood compared with vehicle.Metabolomics, 2019
In obese mice, glutathione and sphingolipid metabolism changed the most after HNG treatment.Metabolomics, 2019

Humanin studies on side effects

3 results · people 0 · animals 3 · lab 0

3 results

In mice with human tumor grafts, HNG reduced the spleen weight loss that TMZ caused.Experimental and molecular pathology, 2019
In mice, HNG did not make bleeding time longer than saline.Journal of cellular and molecular medicine, 2020
In mice with human tumor grafts, HNG reduced the liver weight loss that TMZ caused.Experimental and molecular pathology, 2019

Humanin studies on weight and appetite

3 results · people 0 · animals 3 · lab 0

3 results

In rats with PCOS, added humanin reduced weight gain.Molecular human reproduction, 2021
In mice with human tumor grafts, HNG reduced the body weight loss that TMZ caused.Experimental and molecular pathology, 2019
In female mice with chemotherapy-induced ovary damage, humanin alone limited the loss of body weight.Reproductive toxicology, 2025

Humanin studies on muscles and tendons

4 results · people 0 · animals 2 · lab 2

Top 3 of 4 results

In mice, adding HNG to glucocorticoids did not make muscle damage worse.Biochemistry and biophysics reports, 2026
In mice, HNG slightly enlarged muscle fibers.Biochemistry and biophysics reports, 2026
In lab-grown human muscle cells, a humanin analogue kept the cells larger when dexamethasone was present, compared with dexamethasone alone.Physiological reports, 2026

Humanin studies on daily life and fitness

2 results · people 0 · animals 2 · lab 0

2 results

In mice, the humanin derivative S14G-HN did not change movement in either test.Neuropeptides, 2017
In mice, HNG did not change physical activity.Biochimica et biophysica acta. General subjects, 2022

Humanin studies on growth hormone and growth

2 results · people 0 · animals 2 · lab 0

2 results

In mice, IGF-1 levels fell over time after an injection of the humanin analogue HNG.Endocrinology, 2013
In mice, IGFBP-3 levels fell over time after an injection of the humanin analogue HNG.Endocrinology, 2013

Humanin studies on mood, stress and behavior

2 results · people 0 · animals 2 · lab 0

2 results

In mice, the humanin derivative S14G-HN did not change anxiety-related behavior.Neuropeptides, 2017
In mice, humanin given into the brain ventricles produced an anxiety-reducing effect.Peptides, 2016

Humanin studies on sexual and women's health

2 results · people 0 · animals 2 · lab 0

2 results

In male rats given paroxetine, humanin restored ejaculatory frequency.Reproductive biology, 2026
In male rats given paroxetine, humanin restored copulatory efficiency.Reproductive biology, 2026

Trials and papers

Humanin trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

0 trials match. Highest phase first. Data from ClinicalTrials.gov.

No trial matches these filters.

7 more mention it but do not test it. They are not trials of Humanin: they only measure it (a blood level or an eligibility term) or name it in their text.

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

532 studies match. Retracted studies are left out.

Showing 20 of 532 studiesquery qry_ffe4284f878701e57c2ad51c

Studies with results

375 studies in all, 14 on this page

In vitro (cells) · 2003

7 results

Humanin peptide suppresses apoptosis by interfering with Bax activation.

Guo et al. 2003Naturecited by 503

PMID 12732850DOI 10.1038/nature01627PUB-12732850

Full text at the publisher5 results where Humanin was given (plus 2 on tools or combinations, listed separately)

Publisher page See results (7)

In vitro (cells) · mouse · 2003

8 results

Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis.

Ikonen et al. 2003Proceedings of the National Academy of Sciences of the United States of Americacited by 225

PMID 14561895PMC240741DOI 10.1073/pnas.2135111100PUB-14561895

Rights unknown5 results where Humanin was given (plus 1 on natural levels and 2 on tools or combinations, listed separately)

Source link See results (8)

Animal study (in vivo) · 2009

10 results

Humanin: a novel central regulator of peripheral insulin action.

Muzumdar et al. 2009PloS onecited by 217

PMID 19623253PMC2709436DOI 10.1371/journal.pone.0006334PUB-19623253

CC BY4 results where Humanin was given (plus 3 on natural levels and 3 on tools or combinations, listed separately)

Download PDF See results (10)

Measured the body's own Humanin · 2017

1 result

Whole-transcriptome brain expression and exon-usage profiling in major depression and suicide: evidence for altered glial, endothelial and ATPase activity.

Pantazatos et al. 2017Molecular psychiatrycited by 199

PMID 27528462PMC5313378DOI 10.1038/mp.2016.130PUB-27528462

Rights unknown1 result on the body's own Humanin. Nobody was given Humanin.

Source link See results (1)

In vitro (cells) · 2001

5 results

Mechanisms of neuroprotection by a novel rescue factor humanin from Swedish mutant amyloid precursor protein.

Hashimoto et al. 2001Biochemical and biophysical research communicationscited by 185

PMID 11327724DOI 10.1006/bbrc.2001.4765PUB-11327724

Full text at the publisher1 result where Humanin was given (plus 4 on tools or combinations, listed separately)

Publisher page See results (5)

Not a test of Humanin alone · 2009

3 results

Amyloid-beta causes memory impairment by disturbing the JAK2/STAT3 axis in hippocampal neurons.

Chiba et al. 2009Molecular psychiatrycited by 179

PMID 18813209DOI 10.1038/mp.2008.105PUB-18813209

Rights unknown1 result where Humanin was a tool, carrier or part of a combination

Source link See results (3)

In vitro (cells) · 2001

6 results

Detailed characterization of neuroprotection by a rescue factor humanin against various Alzheimer's disease-relevant insults.

Hashimoto et al. 2001The Journal of neuroscience : the official journal of the Society for Neurosciencecited by 173

PMID 11717357PMC6763898DOI 10.1523/jneurosci.21-23-09235.2001PUB-11717357

Rights unknown6 results where Humanin was given

Source link See results (6)

In vitro (cells) · 2004

4 results

Humanin, a newly identified neuroprotective factor, uses the G protein-coupled formylpeptide receptor-like-1 as a functional receptor.

Ying et al. 2004Journal of immunology (Baltimore, Md. : 1950)cited by 170

PMID 15153530DOI 10.4049/jimmunol.172.11.7078PUB-15153530

Full text at the publisher4 results where Humanin was given

Publisher page See results (4)

In vitro (cell-free) · 2009

5 results

Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor alpha/WSX-1/gp130.

Hashimoto et al. 2009Molecular biology of the cellcited by 169

PMID 19386761DOI 10.1091/mbc.e09-02-0168PUB-19386761

Rights unknown1 result where Humanin was given (plus 4 on tools or combinations, listed separately)

Source link See results (5)

Measured the body's own Humanin · 2019

4 results

Human Aging and Longevity Are Characterized by High Levels of Mitokines.

Conte et al. 2019The journals of gerontology. Series A, Biological sciences and medical sciencescited by 163

PMID 29955888DOI 10.1093/gerona/gly153PUB-29955888

Full text at the publisher4 results on the body's own Humanin. Nobody was given Humanin.

Publisher page See results (4)

In vitro (cells) · 2016

12 results

The Mitochondrial-Derived Peptide Humanin Protects RPE Cells From Oxidative Stress, Senescence, and Mitochondrial Dysfunction.

Sreekumar et al. 2016Investigative ophthalmology & visual sciencecited by 160

PMID 26990160PMC4811181DOI 10.1167/iovs.15-17053PUB-26990160

Free to read · publisher termsCC BY-NC-ND9 results where Humanin was given (plus 3 on natural levels, listed separately)

Read at source See results (12)

Animal study (in vivo) · mouse · 2006

9 results

Humanin is a novel neuroprotective agent against stroke.

Xu et al. 2006Strokecited by 154

PMID 16960089DOI 10.1161/01.str.0000242772.94277.1fPUB-16960089

Full text at the publisher9 results where Humanin was given

Publisher page See results (9)

In vitro (cells) · 2010

5 results

Humanin is expressed in human vascular walls and has a cytoprotective effect against oxidized LDL-induced oxidative stress.

Bachar et al. 2010Cardiovascular researchcited by 152

PMID 20562421PMC2952532DOI 10.1093/cvr/cvq191PUB-20562421

Rights unknown3 results where Humanin was given (plus 2 on natural levels, listed separately)

Source link See results (5)

Animal study (in vivo) · mouse · 2010

9 results

Acute humanin therapy attenuates myocardial ischemia and reperfusion injury in mice.

Muzumdar et al. 2010Arteriosclerosis, thrombosis, and vascular biologycited by 142

PMID 20651283PMC2941397DOI 10.1161/atvbaha.110.205997PUB-20651283

Rights unknown9 results where Humanin was given

Source link See results (9)

More studies

92 studies in all, 6 on this page

Indexing hint: In vitro study · 2001

Corrected

A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta.

Hashimoto et al. 2001Proceedings of the National Academy of Sciences of the United States of Americacited by 553

PMID 11371646PMC33469DOI 10.1073/pnas.101133498PUB-11371646

Rights unknown

Source link Read the notice

PubMed tag: Review · 2006

Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses.

Migeotte et al. 2006Cytokine & growth factor reviewscited by 373

PMID 17084101DOI 10.1016/j.cytogfr.2006.09.009PUB-17084101

Full text at the publisher

Publisher page

PubMed tag: Review · 2013

The emerging role of the mitochondrial-derived peptide humanin in stress resistance.

Yen et al. 2013Journal of molecular endocrinologycited by 182

PMID 23239898PMC3705736DOI 10.1530/jme-12-0203PUB-23239898

Rights unknown

Source link

PubMed tag: review-article, Review · 2020

Senescence in the pathogenesis of age-related macular degeneration.

Blasiak et al. 2020Cellular and molecular life sciences : CMLScited by 152

PMID 31897543PMC11105088DOI 10.1007/s00018-019-03420-xPUB-31897543

Rights unknown

Source link

PubMed tag: review-article, Review · 2013

Distinct signaling cascades elicited by different formyl peptide receptor 2 (FPR2) agonists.

Cattaneo et al. 2013International journal of molecular sciencescited by 150

PMID 23549262PMC3645683DOI 10.3390/ijms14047193PUB-23549262

CC BY

Download PDF

PubMed tag: review-article · 2006

Neuronal cell death in Alzheimer's disease and a neuroprotective factor, humanin.

Niikura et al. 2006Current neuropharmacologycited by 140

PMID 18615127PMC2430668DOI 10.2174/157015906776359577PUB-18615127

Rights unknown

Source link

No result for Humanin (5 studies on this page, 65 in all)

These studies name Humanin but give no result for it (for example, the results concern another peptide in the study).

PubMed tag: none · 2015

6 results

The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.

Lee et al. 2015Cell metabolismcited by 584

PMID 25738459PMC4350682DOI 10.1016/j.cmet.2015.02.009PUB-25738459

Rights unknown6 results

Source link See results (6)

PubMed tag: none · 2016

Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers.

Cobb et al. 2016Agingcited by 232

PMID 27070352PMC4925829DOI 10.18632/aging.100943PUB-27070352

CC BY

Download PDF

PubMed tag: none · 2013

Humanin: a harbinger of mitochondrial-derived peptides?

Lee et al. 2013Trends in endocrinology and metabolism: TEMcited by 225

PMID 23402768PMC3641182DOI 10.1016/j.tem.2013.01.005PUB-23402768

Rights unknown

Source link

PubMed tag: Review · 2016

MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism.

Lee et al. 2016Free radical biology & medicinecited by 148

PMID 27216708PMC5116416DOI 10.1016/j.freeradbiomed.2016.05.015PUB-27216708

Rights unknown

Source link

PubMed tag: Review · 2017

Mitochondrially derived peptides as novel regulators of metabolism.

Kim et al. 2017The Journal of physiologycited by 147

PMID 28574175DOI 10.1113/jp274472PUB-28574175

Rights unknown

Source link

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

Humanin studies: 375 papers with results

Page 1 of 8

Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction.
Liao Y · Biomedicines · 2026
Animal study (in vivo) · mouse · 26 results
Humanin prevents intra-renal microvascular remodeling and inflammation in hypercholesterolemic ApoE deficient mice.
Zhang X · Life sciences · 2012
Animal study (in vivo) · mouse · 11 results
Humanin ameliorates diabetes-induced testicular damage in a streptozotocin-induced mouse model.
Hekim MG · Experimental physiology · 2026
Animal study (in vivo) · mouse · 5 results
Humanin Restores Metabolic Hormone Homeostasis of Leptin, Ghrelin, Irisin and Asprosin in Streptozotocin-Induced Diabetic Mice.
Bulut F · Metabolites · 2026
Animal study (in vivo) · mouse · 4 results
Humanin peptide ameliorates reproductive dysfunction and restores neuroendocrine mechanisms in SSRI-treated male rats.
Köm Akipek RE · Reproductive biology · 2026
Animal study (in vivo) · rat · 6 results
Repeated Humanin Treatment Attenuates Oxidative Stress, Inflammation, and Apoptosis in Diabetic Cardiac Tissue.
Bulut F · Biology · 2026
Animal study (in vivo) · mouse · 5 results
Chronic treatment with the mitochondrial peptide humanin prevents age-related myocardial fibrosis in mice.
Qin Q · American journal of physiology. Heart and circulatory physiology · 2018
Animal study (in vivo) · mouse · 8 results
Effect of humanine on the Notch signaling pathway in myocardial infarction.
Onat E · Turkish journal of medical sciences · 2023
Animal study (in vivo) · rat · 10 results
Humanin's impact on pain markers and neuronal viability in diabetic neuropathy model.
Kelestemur MM · Archives of physiology and biochemistry · 2024
Animal study (in vivo) · mouse · 6 results
Metabolomic profile of diet-induced obesity mice in response to humanin and small humanin-like peptide 2 treatment.
Mehta HH · Metabolomics : Official journal of the Metabolomic Society · 2019
Animal study (in vivo) · mouse · 3 results
Humanin: a novel central regulator of peripheral insulin action.
Muzumdar RH · PloS one · 2009
Animal study (in vivo) · 10 results
Humanin is a novel neuroprotective agent against stroke.
Xu X · Stroke · 2006
Animal study (in vivo) · mouse · 9 results
Acute humanin therapy attenuates myocardial ischemia and reperfusion injury in mice.
Muzumdar RH · Arteriosclerosis, thrombosis, and vascular biology · 2010
Animal study (in vivo) · mouse · 9 results
The neurosurvival factor Humanin inhibits beta-cell apoptosis via signal transducer and activator of transcription 3 activation and delays and ameliorates diabetes in nonobese diabetic mice.
Hoang PT · Metabolism: clinical and experimental · 2010
Animal study (in vivo) · mouse · 7 results
Synergistic protective effects of humanin and necrostatin-1 on hypoxia and ischemia/reperfusion injury.
Xu X · Brain research · 2010
Animal study (in vivo) · mouse · 5 results
[Gly(14)]-Humanin improved the learning and memory impairment induced by scopolamine in vivo.
Mamiya T · British journal of pharmacology · 2001
Animal study (in vivo) · mouse · 2 results
Humanin preserves endothelial function and prevents atherosclerotic plaque progression in hypercholesterolemic ApoE deficient mice.
Oh YK · Atherosclerosis · 2011
Animal study (in vivo) · mouse · 9 results
The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan.
Yen K · Aging · 2020
Animal study (in vivo) · mouse · 8 results
A humanin derivative, S14G-HN, prevents amyloid-beta-induced memory impairment in mice.
Tajima H · Journal of neuroscience research · 2005
Animal study (in vivo) · mouse · 5 results
Humanin Prevents Age-Related Cognitive Decline in Mice and is Associated with Improved Cognitive Age in Humans.
Yen K · Scientific reports · 2018
Animal study (in vivo) · mouse · 4 results
The mitochondrial-derived peptide humanin activates the ERK1/2, AKT, and STAT3 signaling pathways and has age-dependent signaling differences in the hippocampus.
Kim SJ · Oncotarget · 2016
Animal study (in vivo) · mouse · 7 results
The Mitochondria-Derived Peptide Humanin Improves Recovery from Intracerebral Hemorrhage: Implication of Mitochondria Transfer and Microglia Phenotype Change.
Jung JE · The Journal of neuroscience : the official journal of the Society for Neuroscience · 2020
Animal study (in vivo) · mouse · 12 results
A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice.
Niikura T · PloS one · 2011
Animal study (in vivo) · mouse · 4 results
Humanin regulates oxidative stress in the ovaries of polycystic ovary syndrome patients via the Keap1/Nrf2 pathway.
Wang Y · Molecular human reproduction · 2021
Animal study (in vivo) · rat · 8 results
Pharmacokinetics and tissue distribution of humanin and its analogues in male rodents.
Chin YP · Endocrinology · 2013
Animal study (in vivo) · mouse and rat · 7 results
Opposing roles of insulin-like growth factor binding protein 3 and humanin in the regulation of testicular germ cell apoptosis.
Lue Y · Endocrinology · 2010
Animal study (in vivo) · rat · 2 results
Humanin exerts cardioprotection against cardiac ischemia/reperfusion injury through attenuation of mitochondrial dysfunction.
Thummasorn S · Cardiovascular therapeutics · 2016
Animal study (in vivo) · 6 results
Humanin attenuates Alzheimer-like cognitive deficits and pathological changes induced by amyloid β-peptide in rats.
Chai GS · Neuroscience bulletin · 2014
Animal study (in vivo) · rat · 9 results
The cytoprotective peptide humanin is induced and neutralizes Bax after pro-apoptotic stress in the rat testis.
Jia Y · Andrology · 2013
Animal study (in vivo) · rat · 9 results
S14G-humanin alleviates insulin resistance and increases autophagy in neurons of APP/PS1 transgenic mouse.
Han K · Journal of cellular biochemistry · 2018
Animal study (in vivo) · mouse · 7 results
The effects of humanin and its analogues on male germ cell apoptosis induced by chemotherapeutic drugs.
Jia Y · Apoptosis : an international journal on programmed cell death · 2015
Animal study (in vivo) · mouse · 8 results
High-dose Humanin analogue applied during ischemia exerts cardioprotection against ischemia/reperfusion injury by reducing mitochondrial dysfunction.
Thummasorn S · Cardiovascular therapeutics · 2017
Animal study (in vivo) · rat · 5 results
Protective role of humanin on bortezomib-induced bone growth impairment in anticancer treatment.
Eriksson E · Journal of the National Cancer Institute · 2014
Animal study (in vivo) · mouse · 7 results
Systems spatiotemporal dynamics of traumatic brain injury at single-cell resolution reveals humanin as a therapeutic target.
Arneson D · Cellular and molecular life sciences : CMLS · 2022
Animal study (in vivo) · mouse · 2 results
Humanin is a novel regulator of Hedgehog signaling and prevents glucocorticoid-induced bone growth impairment.
Zaman F · FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019
Animal study (in vivo) · mouse · 11 results
[Gly14]-Humanin offers neuroprotection through glycogen synthase kinase-3β inhibition in a mouse model of intracerebral hemorrhage.
Wang T · Behavioural brain research · 2013
Animal study (in vivo) · mouse · 11 results
Humanin Promotes Tumor Progression in Experimental Triple Negative Breast Cancer.
Moreno Ayala MA · Scientific reports · 2020
Animal study (in vivo) · mouse · 10 results
Humanin Exerts Neuroprotection During Cardiac Ischemia-Reperfusion Injury.
Kumfu S · Journal of Alzheimer's disease : JAD · 2018
Animal study (in vivo) · rat · 7 results
Humanin analog enhances the protective effect of dexrazoxane against doxorubicin-induced cardiotoxicity.
Lue Y · American journal of physiology. Heart and circulatory physiology · 2018
Animal study (in vivo) · mouse · 8 results
Humanin-induced autophagy plays important roles in skeletal muscle function and lifespan extension.
Kim SJ · Biochimica et biophysica acta. General subjects · 2022
Animal study (in vivo) · c. elegans and mouse · 4 results
[Gly14]-Humanin Protects Against Amyloid β Peptide-Induced Impairment of Spatial Learning and Memory in Rats.
Yuan L · Neuroscience bulletin · 2016
Animal study (in vivo) · rat · 3 results
Intranasal delivery of mitochondrial protein humanin rescues cell death and promotes mitochondrial function in Parkinson's disease.
Kim KH · Theranostics · 2023
Animal study (in vivo) · mouse · 8 results
Humanin Specifically Interacts with Amyloid-β Oligomers and Counteracts Their in vivo Toxicity.
Romeo M · Journal of Alzheimer's disease : JAD · 2017
Animal study (in vivo) · caenorhabditis elegans · 8 results
Humanin prevents brain mitochondrial dysfunction in a cardiac ischaemia-reperfusion injury model.
Kumfu S · Experimental physiology · 2016
Animal study (in vivo) · rat · 4 results
The Neurovascular Protective Effect of S14G-Humanin in a Murine MCAO Model and Brain Endothelial Cells.
Peng T · IUBMB life · 2018
Animal study (in vivo) · mouse · 19 results
Humanin protects against chemotherapy-induced stage-specific male germ cell apoptosis in rats.
Surampudi P · Andrology · 2015
Animal study (in vivo) · rat · 4 results
Efficacy of a Novel Mitochondrial-Derived Peptide in a Porcine Model of Myocardial Ischemia/Reperfusion Injury.
Sharp TE 3rd · JACC. Basic to translational science · 2020
Animal study (in vivo) · pig · 2 results
[Gly(14)]-humanin rescues long-term potentiation from amyloid beta protein-induced impairment in the rat hippocampal CA1 region in vivo.
Guo F · Synapse (New York, N.Y.) · 2010
Animal study (in vivo) · rat · 2 results
Protective effects of chronic humanin treatment in mice with diabetic encephalopathy: A focus on oxidative stress, inflammation, and apoptosis.
Bulut F · Behavioural brain research · 2023
Animal study (in vivo) · mouse · 4 results
Humanin Alleviates Insulin Resistance in Polycystic Ovary Syndrome: A Human and Rat Model-Based Study.
Wang Y · Endocrinology · 2021
Animal study (in vivo) · rat · 9 results

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	No Drugs@FDA record: openFDA drugsfda searches on openfda.generic_name for humanin, colivelin and S14G returned NOT_FOUND on 2026-10-13. The FDA orphan drug designation database was not checked.	13 Oct 2026	fda.gov (opens in a new tab)
EU	EMA	No match for humanin or colivelin in the EMA medicines data file (timestamp 2026-10-13T06:02:34Z, 2,748 records) or in the EMA orphan designation data file (timestamp 2026-10-13T06:05:30Z, 3,310 records). Both files were downloaded on 2026-10-13 and searched as text.	13 Oct 2026	ema.europa.eu (opens in a new tab)
Sport	WADA	Banned in sport (WADA S0) S0 covers substances not approved for human use; Humanin is not named on the List.	2026 List	wada-ama.org (opens in a new tab)
World (WADA 2027 list)	Note	Humanin is not named. The S0 class applies by its wording, as for the 2026 List. The 2027 S0 text lists 'peptides' as an example of non-approved substances.	13 Oct 2026	wada-ama.org (opens in a new tab)
Russia	Note	A name search of the RLS medicine encyclopedia (rlsnet.ru) for 'humanin', and for the Russian spellings 'гуманин' and 'хуманин', returned a results page with no entries on 2026-10-13. A control search for 'семаглутид' returned entries. The State Register of Medicines (grls.rosminzdrav.ru) was not searched directly, because its search is a form.	13 Oct 2026	rlsnet.ru (opens in a new tab)
Japan, Australia, Canada, other regions	Note	not checked	13 Oct 2026	Not recorded

Safety outcomes

6 safety results for Humanin.

No safety results from studies in people

The safety results below come from animal or lab studies. They do not show what happens in people.

Animal evidence· 5

In mice not given Dox, HNG had no adverse effect on the heart.
Animal study (in vivo)mouse
Bleeding time was not prolonged in mice receiving HNG compared with saline.
Animal study (in vivo)mouse
In mice, S14G-HN had no effect on locomotor activity in either the object recognition or the zero-maze test.
Animal study (in vivo)mouse
In wild-type young mice, HNG did not affect physical activity.
Animal study (in vivo)mouse
Adding HNG to glucocorticoids did not exacerbate skeletal muscle pathology in mdx mice.
Animal study (in vivo)mouse

Lab evidence· 1

In COV434 granulosa cells, HNG treatment did not cause abnormal cell proliferation.
In vitro (cells)human

Doses studied · 57

The doses that these studies used. They are not recommendations.

4 mg/kg/dayAnimal
Species
mouse
Route
intraperitoneal
Duration
16 weeks
Design
Animal study (in vivo) · n = 24
4 mg/kgAnimal
Species
mouse
Route
intraperitoneal
Duration
15 days
Design
Animal study (in vivo) · n = 20
4 mg/kg/dayAnimal
Species
mouse
Route
intraperitoneal
Duration
15 days
Design
Animal study (in vivo) · n = 20
1 mg/kg/dayAnimal
Species
rat
Route
subcutaneous infusion
Duration
Not reported
Design
Animal study (in vivo) · n = 20
4 mg/kgAnimal
Species
mouse
Route
Not reported
Duration
15 consecutive days
Design
Animal study (in vivo) · n = 20
4 mg/kg 2 times/wkAnimal
Species
mouse
Route
intraperitoneal
Duration
14 months
Design
Animal study (in vivo) · n = 14

Doses studied in the study results, as given in the studies.
Dose as reported	Class	Species	Route	Duration	Design
4 mg/kg/day	Animal	mouse	intraperitoneal	16 weeks	Animal study (in vivo) · n = 24
4 mg/kg	Animal	mouse	intraperitoneal	15 days	Animal study (in vivo) · n = 20
4 mg/kg/day	Animal	mouse	intraperitoneal	15 days	Animal study (in vivo) · n = 20
1 mg/kg/day	Animal	rat	subcutaneous infusion	Not reported	Animal study (in vivo) · n = 20
4 mg/kg	Animal	mouse	Not reported	15 consecutive days	Animal study (in vivo) · n = 20
4 mg/kg 2 times/wk	Animal	mouse	intraperitoneal	14 months	Animal study (in vivo) · n = 14

6 of 57 shown

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000055
Peptide version: 6
Peptide hash: 5e1d84c66681b824…
Data version: 308560

Latest changes

27 Oct 2026UpdatedData version 256704
22 Oct 2026UpdatedData version 254532
21 Oct 2026UpdatedData version 213628
14 Oct 2026UpdatedData version 194699
13 Oct 2026UpdatedData version 188876
13 Oct 2026CreatedData version 175773

For developers

curl -s https://pepbank.io/v1/briefs/humanin

Evidence summary for Humanin: counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

Outcome group	Human	Animal	Lab	Computer model	Total
NeuroprotectionWhole body	No results	Animal: 93 results from 22 studies: 29 increase, 46 decrease, 12 no significant change, 6 not reported. Strongest design: Animal study (in vivo)	Lab: 115 results from 51 studies: 35 increase, 62 decrease, 11 no significant change, 2 mixed, 5 not reported. Strongest design: Ex vivo tissue	No results	208
Receptor activity and mechanismWhole body	No results	Animal: 50 results from 24 studies: 25 increase, 11 decrease, 9 no significant change, 1 mixed, 4 not reported. Strongest design: Animal study (in vivo)	Lab: 139 results from 61 studies: 41 increase, 38 decrease, 13 no significant change, 2 mixed, 45 not reported. Strongest design: Ex vivo tissue	Computer model: 4 results from 1 study: 1 decrease, 1 no significant change, 2 not reported. Strongest design: In silico	193
Inflammation markersSkin and wound	No results	Animal: 79 results from 29 studies: 5 increase, 60 decrease, 10 no significant change, 4 not reported. Strongest design: Animal study (in vivo)	Lab: 50 results from 14 studies: 2 increase, 48 decrease. Strongest design: Ex vivo tissue	No results	129
Mitochondrial functionWhole body	No results	Animal: 26 results from 13 studies: 11 increase, 10 decrease, 2 no significant change, 3 not reported. Strongest design: Animal study (in vivo)	Lab: 59 results from 24 studies: 36 increase, 16 decrease, 2 no significant change, 5 not reported. Strongest design: Ex vivo tissue	No results	85
Sex hormones and fertilityReproductive and sexual health	No results	Animal: 46 results from 16 studies: 20 increase, 18 decrease, 5 no significant change, 3 mixed. Strongest design: Animal study (in vivo)	Lab: 31 results from 9 studies: 22 increase, 5 decrease, 3 no significant change, 1 not reported. Strongest design: Ex vivo tissue	No results	77
Oxidative stressWhole body	No results	Animal: 27 results from 12 studies: 13 increase, 12 decrease, 2 not reported. Strongest design: Animal study (in vivo)	Lab: 26 results from 13 studies: 5 increase, 18 decrease, 3 no significant change. Strongest design: Ex vivo tissue	No results	53
Heart functionCardiovascular	No results	Animal: 43 results from 10 studies: 6 increase, 34 decrease, 2 no significant change, 1 not reported. Strongest design: Animal study (in vivo)	Lab: 4 results from 2 studies: 4 decrease. Strongest design: In vitro (cells)	No results	47
Bone and jointMusculoskeletal	No results	Animal: 13 results from 7 studies: 4 increase, 8 decrease, 1 no significant change. Strongest design: Animal study (in vivo)	Lab: 23 results from 6 studies: 6 increase, 15 decrease, 1 mixed, 1 not reported. Strongest design: Ex vivo tissue	No results	36
Cell viability and deathSkin and wound	No results	Animal: 7 results from 2 studies: 3 increase, 4 decrease. Strongest design: Animal study (in vivo)	Lab: 27 results from 12 studies: 9 increase, 18 decrease. Strongest design: Ex vivo tissue	No results	34
Cognition and memoryNervous system and cognition	No results	Animal: 24 results from 15 studies: 13 increase, 5 decrease, 3 no significant change, 3 not reported. Strongest design: Animal study (in vivo)	Lab: 2 results from 1 study: 2 increase. Strongest design: Ex vivo tissue	No results	26
Kidney functionKidney and urinary	No results	Animal: 15 results from 5 studies: 2 increase, 10 decrease, 2 no significant change, 1 not reported. Strongest design: Animal study (in vivo)	Lab: 1 result from 1 study: 1 not reported. Strongest design: In vitro (cells)	No results	16
Tumor growthCancer	No results	Animal: 9 results from 4 studies: 4 increase, 3 decrease, 2 no significant change. Strongest design: Animal study (in vivo)	Lab: 5 results from 5 studies: 3 increase, 1 decrease, 1 no significant change. Strongest design: In vitro (cells)	No results	14

Outcome group	Human	Animal	Lab	Computer model	All
Mitochondrial functionWhole body	58	10	18	–	86
Aging markersWhole body	41	26	4	–	71
Sex hormones and fertilityReproductive and sexual health	25	34	3	–	62
Endogenous peptide levelsWhole body	47	1	5	–	53
Cardiovascular eventsCardiovascular	16	–	–	–	16
Exercise and physical functionWhole body	10	3	–	–	13
Inflammation markersRespiratory	10	1	–	–	11
NeuroprotectionNervous system and cognition	1	5	4	–	10
Receptor activity and mechanismReproductive and sexual health	1	1	8	–	10
Glycemic controlMetabolic and weight	7	1	–	–	8
LipidsMetabolic and weight	5	–	–	–	5
Lung injury and fibrosisCardiovascular	4	1	–	–	5
Bone and jointMusculoskeletal	2	–	2	–	4
Cell viability and deathWhole body	–	1	3	–	4
Heart functionCardiovascular	1	3	–	–	4
Oxidative stressReproductive and sexual health	4	–	–	–	4
Cancer biomarkers and prognosisCancer	3	–	–	–	3
Tumor growthCancer	3	–	–	–	3
Blood pressureCardiovascular	2	–	–	–	2
Cardiometabolic risk factorsMetabolic and weight	2	–	–	–	2
Cognition and memoryNervous system and cognition	2	–	–	–	2
Kidney functionKidney and urinary	2	–	–	–	2
Liver fat and liver functionMetabolic and weight	2	–	–	–	2
MortalityWhole body	2	–	–	–	2
Anxiety and moodMental health and mood	1	–	–	–	1
Body compositionRespiratory	1	–	–	–	1
Immune responseImmune and inflammation	1	–	–	–	1
Infection and antimicrobial activityInfection	1	–	–	–	1
All outcome groups	254	87	47	–	388

Outcome group	Human	Animal	Lab	Computer model	Total
NeuroprotectionWhole body	No results	Animal: 93 results from 22 studies: 29 increase, 46 decrease, 12 no significant change, 6 not reported. Strongest design: Animal study (in vivo)	Lab: 115 results from 51 studies: 35 increase, 62 decrease, 11 no significant change, 2 mixed, 5 not reported. Strongest design: Ex vivo tissue	No results	208
Receptor activity and mechanismWhole body	No results	Animal: 50 results from 24 studies: 25 increase, 11 decrease, 9 no significant change, 1 mixed, 4 not reported. Strongest design: Animal study (in vivo)	Lab: 139 results from 61 studies: 41 increase, 38 decrease, 13 no significant change, 2 mixed, 45 not reported. Strongest design: Ex vivo tissue	Computer model: 4 results from 1 study: 1 decrease, 1 no significant change, 2 not reported. Strongest design: In silico	193
Inflammation markersSkin and wound	No results	Animal: 79 results from 29 studies: 5 increase, 60 decrease, 10 no significant change, 4 not reported. Strongest design: Animal study (in vivo)	Lab: 50 results from 14 studies: 2 increase, 48 decrease. Strongest design: Ex vivo tissue	No results	129
Mitochondrial functionWhole body	No results	Animal: 26 results from 13 studies: 11 increase, 10 decrease, 2 no significant change, 3 not reported. Strongest design: Animal study (in vivo)	Lab: 59 results from 24 studies: 36 increase, 16 decrease, 2 no significant change, 5 not reported. Strongest design: Ex vivo tissue	No results	85
Sex hormones and fertilityReproductive and sexual health	No results	Animal: 46 results from 16 studies: 20 increase, 18 decrease, 5 no significant change, 3 mixed. Strongest design: Animal study (in vivo)	Lab: 31 results from 9 studies: 22 increase, 5 decrease, 3 no significant change, 1 not reported. Strongest design: Ex vivo tissue	No results	77
Oxidative stressWhole body	No results	Animal: 27 results from 12 studies: 13 increase, 12 decrease, 2 not reported. Strongest design: Animal study (in vivo)	Lab: 26 results from 13 studies: 5 increase, 18 decrease, 3 no significant change. Strongest design: Ex vivo tissue	No results	53
Heart functionCardiovascular	No results	Animal: 43 results from 10 studies: 6 increase, 34 decrease, 2 no significant change, 1 not reported. Strongest design: Animal study (in vivo)	Lab: 4 results from 2 studies: 4 decrease. Strongest design: In vitro (cells)	No results	47
Bone and jointMusculoskeletal	No results	Animal: 13 results from 7 studies: 4 increase, 8 decrease, 1 no significant change. Strongest design: Animal study (in vivo)	Lab: 23 results from 6 studies: 6 increase, 15 decrease, 1 mixed, 1 not reported. Strongest design: Ex vivo tissue	No results	36
Cell viability and deathSkin and wound	No results	Animal: 7 results from 2 studies: 3 increase, 4 decrease. Strongest design: Animal study (in vivo)	Lab: 27 results from 12 studies: 9 increase, 18 decrease. Strongest design: Ex vivo tissue	No results	34
Cognition and memoryNervous system and cognition	No results	Animal: 24 results from 15 studies: 13 increase, 5 decrease, 3 no significant change, 3 not reported. Strongest design: Animal study (in vivo)	Lab: 2 results from 1 study: 2 increase. Strongest design: Ex vivo tissue	No results	26
Kidney functionKidney and urinary	No results	Animal: 15 results from 5 studies: 2 increase, 10 decrease, 2 no significant change, 1 not reported. Strongest design: Animal study (in vivo)	Lab: 1 result from 1 study: 1 not reported. Strongest design: In vitro (cells)	No results	16
Tumor growthCancer	No results	Animal: 9 results from 4 studies: 4 increase, 3 decrease, 2 no significant change. Strongest design: Animal study (in vivo)	Lab: 5 results from 5 studies: 3 increase, 1 decrease, 1 no significant change. Strongest design: In vitro (cells)	No results	14

Outcome group	Human	Animal	Lab	Computer model	All
Mitochondrial functionWhole body	58	10	18	–	86
Aging markersWhole body	41	26	4	–	71
Sex hormones and fertilityReproductive and sexual health	25	34	3	–	62
Endogenous peptide levelsWhole body	47	1	5	–	53
Cardiovascular eventsCardiovascular	16	–	–	–	16
Exercise and physical functionWhole body	10	3	–	–	13
Inflammation markersRespiratory	10	1	–	–	11
NeuroprotectionNervous system and cognition	1	5	4	–	10
Receptor activity and mechanismReproductive and sexual health	1	1	8	–	10
Glycemic controlMetabolic and weight	7	1	–	–	8
LipidsMetabolic and weight	5	–	–	–	5
Lung injury and fibrosisCardiovascular	4	1	–	–	5
Bone and jointMusculoskeletal	2	–	2	–	4
Cell viability and deathWhole body	–	1	3	–	4
Heart functionCardiovascular	1	3	–	–	4
Oxidative stressReproductive and sexual health	4	–	–	–	4
Cancer biomarkers and prognosisCancer	3	–	–	–	3
Tumor growthCancer	3	–	–	–	3
Blood pressureCardiovascular	2	–	–	–	2
Cardiometabolic risk factorsMetabolic and weight	2	–	–	–	2
Cognition and memoryNervous system and cognition	2	–	–	–	2
Kidney functionKidney and urinary	2	–	–	–	2
Liver fat and liver functionMetabolic and weight	2	–	–	–	2
MortalityWhole body	2	–	–	–	2
Anxiety and moodMental health and mood	1	–	–	–	1
Body compositionRespiratory	1	–	–	–	1
Immune responseImmune and inflammation	1	–	–	–	1
Infection and antimicrobial activityInfection	1	–	–	–	1
All outcome groups	254	87	47	–	388